Ulrich Lehmann

Prof. Ulrich Lehmann

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2007 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
ULUlrich Lehmann
Ulrich Lehmann
BHB Hasemeier
B Hasemeier
MCM Christgen
M Christgen
MMM Müller
M Müller
DRD Römermann
D Römermann
HKH Kreipe
H Kreipe

1 December 2001 in Methods
Verified
Journal Article
Closed access
ULUlrich Lehmann
Ulrich Lehmann
HKHans Kreipe
Hans Kreipe

1 February 2002 in The American Journal of Pathology
Verified
Journal Article
Closed access
ULUlrich Lehmann
Ulrich Lehmann
FLFlorian Länger
Florian Länger
HFHenning Feist
Henning Feist
SGSabine Glöckner
Sabine Glöckner
BHBritta Hasemeier
Britta Hasemeier
HKHans Kreipe
Hans Kreipe

Verified
Journal Article
Open access
PDF file
SASumadi Lukman Anwar
Sumadi Lukman Anwar
WWWahyu Wulaningsih
Wahyu Wulaningsih
ULUlrich Lehmann
Ulrich Lehmann
Transposable elements (TEs) comprise nearly half of the human genome and play an essential role in the maintenance of genomic stability, chromosomal architecture, and transcriptional regulation. TEs are repetitive sequences consisting of RNA transposons, DNA transposons, and endogenous retroviruses that can invade the human genome with a substantial contribution in human evolution and genomic diversity. TEs are therefore firmly regulated from early embryonic development and during the entire course of human life by epigenetic mechanisms, in particular DNA methylation and histone modifications. The deregulation of TEs has been reported in some developmental diseases, as well as for different types of human cancers. To date, the role of TEs, the mechanisms underlying TE reactivation, and the interplay with DNA methylation in human cancers remain largely unexplained. We reviewed the loss of epigenetic regulation and subsequent genomic instability, chromosomal aberrations, transcriptional deregulation, oncogenic activation, and aberrations of non-coding RNAs as the potential mechanisms underlying TE deregulation in human cancers.

8 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SASumadi Lukman Anwar
Sumadi Lukman Anwar
TKTill Krech
Till Krech
BHBritta Hasemeier
Britta Hasemeier
ESElisa Schipper
Elisa Schipper
NSNora Schweitzer
Nora Schweitzer
ULUlrich Lehmann
Ulrich Lehmann
Deregulation of imprinted genes is an important molecular mechanism contributing to the development of cancer in humans. However, knowledge about imprinting defects in human hepatocellular carcinoma (HCC), the third leading cause of cancer mortality worldwide, is still limited. Therefore, a systematic meta-analysis of the expression of 223 imprinted loci in human HCC was initiated. This screen revealed that the DLK1-MEG3 locus is frequently deregulated in HCC. Deregulation of DLK1 and MEG3 expression accompanied by extensive aberrations in DNA methylation could be confirmed experimentally in an independent series of human HCC (n = 40) in more than 80% of cases. Loss of methylation at the DLK1-MEG3 locus correlates linearly with global loss of DNA methylation in HCC (r2 = 0.63, p<0.0001). Inhibition of DNMT1 in HCC cells using siRNA led to a reduction in MEG3-DMR methylation and concomitant increase in MEG3 RNA expression. Allele-specific expression analysis identified loss of imprinting in 10 out of 31 informative samples (32%), rendering it one of the most frequent molecular defects in human HCC. In 2 cases unequivocal gain of bi-allelic expression accompanied by substantial loss of methylation at the IG-DMR could be demonstrated. In 8 cases the tumour cells displayed allelic switching by mono-allelic expression of the normally imprinted allele. Allelic switching was accompanied by gains or losses of DNA methylation primarily at IG-DMR1. Analysis of 10 hepatocellular adenomas (HCA) and 5 cases of focal nodular hyperplasia (FNH) confirmed that this epigenetic instability is specifically associated with the process of malignant transformation and not linked to increased proliferation per se. This widespread imprint instability in human HCC has to be considered in order to minimize unwanted side-effects of therapeutic approaches targeting the DNA methylation machinery. It might also serve in the future as predictive biomarker and for monitoring response to epigenetic therapy.

23 March 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ULUlrich Lehmann
Ulrich Lehmann
TSThomas Streichert
Thomas Streichert
BOBenjamin Otto
Benjamin Otto
CACord Albat
Cord Albat
BHBritta Hasemeier
Britta Hasemeier
FLFlorian Länger
Florian Länger
The discovery of small non-coding RNAs and the subsequent analysis of microRNA expression patterns in human cancer specimens have provided completely new insights into cancer biology. Genetic and epigenetic data indicate oncogenic or tumor suppressor function of these pleiotropic regulators. Therefore, many studies analyzed the expression and function of microRNA in human breast cancer, the most frequent malignancy in females. However, nothing is known so far about microRNA expression in male breast cancer, accounting for approximately 1% of all breast cancer cases. The expression of 319 microRNAs was analyzed in 9 primary human male breast tumors and in epithelial cells from 15 male gynecomastia specimens using fluorescence-labeled bead technology. For identification of differentially expressed microRNAs data were analyzed by cluster analysis and selected statistical methods. Expression levels were validated for the most up- or down-regulated microRNAs in this training cohort using real-time PCR methodology as well as in an independent test cohort comprising 12 cases of human male breast cancer. Unsupervised cluster analysis separated very well male breast cancer samples and control specimens according to their microRNA expression pattern indicating cancer-specific alterations of microRNA expression in human male breast cancer. miR-21, miR519d, miR-183, miR-197, and miR-493-5p were identified as most prominently up-regulated, miR-145 and miR-497 as most prominently down-regulated in male breast cancer. Male breast cancer displays several differentially expressed microRNAs. Not all of them are shared with breast cancer biopsies from female patients indicating male breast cancer specific alterations of microRNA expression.